Industry
Biotechnology
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Loading...
Open
3.95
Mkt cap
321M
Volume
4.2M
High
4.27
P/E Ratio
-6.52
52-wk high
4.60
Low
3.75
Div yield
N/A
52-wk low
1.26
Portfolio Pulse from
December 16, 2024 | 12:45 pm
Portfolio Pulse from
November 21, 2024 | 12:45 pm
Portfolio Pulse from
November 06, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 4:34 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
October 07, 2024 | 3:26 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 5:29 pm
Portfolio Pulse from Benzinga Newsdesk
October 04, 2024 | 3:14 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.